Physician profile
Scott Pattison
NPI 1023047909
$6,045.64
in general payments reported to CMS, 2019-2025
25 companies · $325 in 2025
The $325 reported for 2025 was less than what a typical Foot & Ankle Surgery provider received nationally (typical 2025 total: $424).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,387 · 2021: $1,617 · 2022: $2,227 · 2023: $147 · 2024: $342 · 2025: $325.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $585 · Education: $229.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $585.25 |
| Education | $228.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Treace Medical Concepts, INC. | $3,482.81 | 2021-2025 | |
| Smith+Nephew, INC. | $981.47 | 2019-2022 | |
| Arthrosurface Incorporated | $427.60 | 2019 | |
| Osiris Therapeutics INC. | $186.42 | 2019 | |
| Stryker Corporation | $136.85 | 2019-2023 | Prostep |
| Djo, LLC | $122.91 | 2019-2025 | Dr Comfort |
| Kerecis Limited | $120.17 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Paratek Pharmaceuticals, INC. | $99.64 | 2024-2025 | Nuzyra |
| Integra Lifesciences Corporation | $62.61 | 2021-2023 | Integra, Integra Dermal Regeneration Template, Primatrix |
| Averitas Pharma INC. | $47.59 | 2024 | Qutenza |
| Ossio INC | $47.42 | 2023 | |
| Melinta Therapeutics, LLC | $44.66 | 2019 | |
| Nevro Corp. | $37.45 | 2022 | |
| Mimedx Group, INC. | $34.60 | 2024 | |
| Organogenesis INC. | $33.85 | 2022-2023 | Puraply |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Anika Therapeutics, INC. | $30.87 | 2021 | |
| Abbott Laboratories | $25.28 | 2025 | Proclaim |
| Grt US Holding, INC. | $23.51 | 2021 | |
| Dynasplint Systems INC. | $20.53 | 2025 | Dynasplint |
| Horizon Therapeutics Plc | $19.21 | 2022 | |
| Ibsa Pharma INC. | $17.05 | 2023 | Tirosint, Licart |
| Depuy Synthes Sales INC. | $14.95 | 2024 | |
| Globus Medical, INC. | $14.27 | 2025 | Senza |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $12.35 | 2022 | |
| Orthofix Medical, INC. | $1.57 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Pattison listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.